A Vitamin D Analog Helps Dismantle Pancreatic Cancer’s Protective Shield in Early Clinical Trial

Pancreatic cancer is one of the hardest cancers to treat, and part of the problem is not just the cancer cells themselves, but what surrounds them. A new early-stage clinical trial suggests that a vitamin D analog already used in medicine for other conditions might help pry open that defensive barrier, making the tumor more vulnerable to chemotherapy.

The shield around the tumor

Pancreatic tumors are typically wrapped in dense, fibrous connective tissue built by activated fibroblasts, cells that normally maintain tissue structure. In a tumor, this fibroblast-rich layer acts like armor: it makes it harder for drugs to penetrate and helps create an environment in which immune cells are kept out. Researchers widely believe this tumor microenvironment contributes to why standard chemotherapy so often falls short.

The idea behind the new trial came from the lab of Ronald Evans at the Salk Institute, who discovered the nuclear receptor superfamily, a group of molecules that switch genes on and off in response to hormones, vitamins and lipids. Roughly 13% of FDA-approved drugs act on these receptors. The vitamin D receptor is one of them. Evans’s team showed in preclinical models that the vitamin D receptor helps regulate fibroblasts in the liver and pancreas, and that synthetic vitamin D analogs such as paricalcitol could calm fibroblast activation. In pancreatic cancer models, this reversed the tumor-supporting behavior of fibroblasts and improved responses to chemotherapy.

From the bench to patients

Working with the Evans team, oncologists Brian Wolpin and Kimberly Perez at the Dana-Farber Cancer Institute ran a randomized, safety-focused trial. It enrolled 36 people with previously untreated metastatic pancreatic cancer. All received standard chemotherapy (gemcitabine plus nab-paclitaxel), combined with either a placebo, intravenous paricalcitol, or oral paricalcitol. Paricalcitol is an FDA-approved drug normally used to treat secondary hyperparathyroidism in people with chronic kidney disease.

The main goal was safety, and the combination passed that test. The most notable side effect was elevated blood calcium, seen in five of the 12 people taking oral paricalcitol, which was managed by reducing the dose.

A key secondary goal was to see whether the drug actually changed the tumor. The team took paired biopsies at the start and again after four to six weeks, then analyzed them with multiplex immunofluorescence and spatial transcriptomics. In patients receiving paricalcitol, fibroblasts were less activated, although their overall numbers did not change, and T cells, the immune cells typically shut out of pancreatic tumors, moved in more readily. This confirmed, in people, the tumor-remodeling effect first seen in the lab.

Early signs of benefit, with caveats

The study was not designed to compare how well the treatments work, so these numbers should be read with caution. Still, partial responses to treatment occurred in 10 of 24 patients (42%) who received paricalcitol, versus one of 12 (9%) in the placebo group. Five patients on paricalcitol were free of disease progression at one year, compared with none on placebo.

Tumors also differed in how much vitamin D receptor they carried. Patients with high receptor levels who received paricalcitol had better chemotherapy responses and the longest overall survival, hinting that receptor expression could one day serve as a biomarker to identify who is most likely to benefit.

What comes next

With only 36 participants, this trial is a proof of principle rather than proof of effectiveness. Larger studies will be needed to test whether pairing vitamin D analogs with chemotherapy, or with other therapies, truly extends survival, and whether tumor vitamin D receptor levels can reliably predict who responds. The researchers also point out that the approach repurposes medications already in routine clinical use, which offers limited commercial return, and that the work depended on public and philanthropic funding.

It is also worth noting that paricalcitol is a prescription drug given under medical supervision in this setting, not the same as over-the-counter vitamin D supplements.

Sources

·         Press release: From Salk Institute discovery to patient care: Vitamin D analog shuts down pancreatic cancer’s shield in clinical trial (Salk Institute, May 26, 2026)

·         Original paper: Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: A rando 

Source: A Vitamin D Analog Helps Dismantle Pancreatic Cancer’s Protective Shield in Early Clinical Trial